Annexon, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 767.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Details
| Name | Annexon, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 92 |
| Founded | 2011 |
| Ipo Date | 2020-07-24 |
| Ceo | Douglas Love |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US03589W1027 |
| Cusip | 03589W102 |
| Cik | 1528115 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Douglas E. Love Esq., J.D. | Chief Executive Officer, President and Director |
| Jennifer Lew CPA | Executive Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Ted Yednock Ph.D. | Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer and Executive Vice President |
| Linda A. Fitzpatrick | Chief Human Resources Officer |
| Michael Overdorf M.B.A. | Executive Vice President and Chief Business Officer |
| Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine |
| Dr. Jamie Dananberg M.D. | Executive Vice President and Chief Medical Officer |
| Shikhar Agarwal M.B.A. | Senior Vice President and Head of Commercial |
| Dr. Sunil Mehta Pharm.D. | Senior Vice President of Medical Affairs |
Contact
| Address | 1400 Sierra Point Parkway, Building C, Brisbane, California 94005, United States |
| Phone | 650 822 5500 |
| Website | https://www.annexonbio.com |